Ivermectin and vaccine injury
TLDRIn this insightful discussion, Professor Robert Clancy, a seasoned physician and researcher, delves into the promising treatment approaches for patients suffering from Long COVID and post-vaccine syndrome. Clancy highlights the potential of a drug called Ivermectin, which has shown to bind effectively with the spike protein, leading to significant improvements in patient symptoms. The conversation underscores the importance of evidence-based communication and the need for further research to solidify these findings. Clancy emphasizes the ethical obligation of medical professionals to explore all avenues for patient relief, advocating for a personalized approach to treatment tailored to individual patient needs. The dialogue also addresses the challenges faced by doctors in adopting repurposed drugs due to bureaucratic constraints, urging a shift towards a more patient-centered healthcare system.
Takeaways
- 📚 Professor Robert Clancy, a renowned physician and researcher, discusses his clinical findings on a new treatment approach for Long COVID and post-vaccine syndrome.
- 🚫 The conversation emphasizes that they are not prescribing medications or advocating self-treatment; instead, they call for further research and clinical trials.
- 🔬 Clancy highlights the use of a drug called Ivermectin, which has shown promise in treating patients with Long COVID by binding to the Spike protein, potentially reducing symptoms.
- 🧬 There is a commonality between post-vaccine and post-infection Long COVID presentations, and both seem to respond to similar treatment approaches.
- 📉 The treatment's effectiveness is demonstrated through patient self-reporting, where significant improvements in symptoms are observed after 4 to 6 weeks of Ivermectin use.
- 📈 After stopping the drug, symptoms tend to rebound, indicating the need for ongoing treatment and further study on dosing and duration.
- 🤔 The discussion raises questions about the long-term safety of Ivermectin, its optimal dosing, and the potential need for regular administration.
- 💡 The potential role of the microbiome in managing COVID-19 and Long COVID is mentioned, suggesting that enhancing immune resilience could be a future avenue of treatment.
- 💊 The use of repurposed drugs like hydroxychloroquine and zinc is discussed, considering their antiviral properties and the possibility of increasing zinc intake within cells.
- 🌐 The conversation underscores the importance of evidence-based communication and the need for global healthcare professionals to engage with new treatment hypotheses.
- 📝 The value of patient engagement and self-advocacy is highlighted, with patients taking an active role in their treatment and even finding alternative methods like transdermal Ivermectin.
Q & A
What is the main topic of discussion in the provided transcript?
-The main topic of discussion is the potential treatment of Long COVID and post-vaccine syndrome using a drug called ivermectin, based on the clinical observations and experiences of Professor Robert Clancy.
What is the significance of the term 'evidence-based communication' mentioned in the transcript?
-The term 'evidence-based communication' refers to the direct sharing of new medical findings and ideas through modern mediums like this discussion, without the need for traditional publications, allowing for quicker dissemination of potentially valuable medical insights.
Why are Professor Clancy and the interviewer emphasizing the importance of not self-administering any medical interventions based on their discussion?
-They emphasize this because the information they are sharing is preliminary and not yet fully validated by larger clinical trials. Self-administration of treatments based on incomplete or unverified data can be dangerous and is not advised.
What is the role of ivermectin as described by Professor Clancy in the treatment of Long COVID and post-vaccine syndrome?
-Ivermectin is described as having a high affinity for binding to the spike protein, which is present in the vaccine and the virus. This binding may help to reduce the symptoms associated with Long COVID and post-vaccine syndrome by preventing the spike protein from causing inflammation and damage to cells.
What are the two types of immune responses related to the spike protein that Professor Clancy discusses?
-The two types of immune responses are one that leads to the classic chronic fatigue symptoms and another that leads to structural damage to nerves, heart, brain, or other organ systems due to the immune system attacking the spike protein.
What is the potential role of vitamin D in managing COVID-19 and related conditions?
-Vitamin D is suggested to play a role in optimizing health and potentially reducing the severity of COVID-19 infection. Ensuring adequate levels of vitamin D is highlighted as an important aspect of overall health.
What does Professor Clancy suggest about the importance of primary care doctors in managing Long COVID?
-Professor Clancy suggests that primary care doctors are crucial as they have a better understanding of the prevalence and importance of certain health issues. They are encouraged to take the information provided and work with their patients to optimize care.
Why does Professor Clancy express frustration with the current approach to treating patients in Long COVID clinics?
-He expresses frustration because, in many cases, patients are not receiving effective treatment. The current approach often involves waiting for symptoms to potentially resolve on their own, rather than actively seeking and applying new treatment options.
What is the significance of the patient's self-treatment using ivermectin cream as mentioned in the transcript?
-The significance is that it demonstrates the desperation and initiative of patients to find relief for their symptoms when conventional treatments are not helping. It also highlights the need for more research and medical guidance on the use of treatments like ivermectin for Long COVID.
How does the discussion on the role of the microbiome in managing COVID-19 and related conditions contribute to the overall conversation?
-The discussion on the microbiome introduces the concept of 'immune resilience' and the idea that enhancing the body's mucosal immune response could potentially reduce the severity of COVID-19 and the occurrence of Long COVID, adding another layer to the treatment strategies.
What is the call to action for the medical community presented by Professor Clancy and the interviewer?
-The call to action is for doctors, nurse practitioners, and pharmacists worldwide to recognize the treatable nature of Long COVID and post-vaccine syndrome, to consider new hypotheses and treatment options, and to engage in evidence-based communication to improve patient outcomes.
Outlines
😀 Introduction and Context Setting
The video begins with a warm welcome to Professor Robert Clancy, a distinguished expert in pathology and medicine. The host expresses excitement about discussing new medical findings directly related to Professor Clancy's clinical work. They clarify that the discussion is not about prescribing medications but rather sharing insights that could lead to further research. The conversation is framed around the potential treatment of Long COVID and post-vaccine syndrome, emphasizing the need for evidence-based communication and the importance of randomized control trials to validate any claims.
🧬 Discussion on Spike Protein and Treatment Approaches
The discussion shifts to the role of the spike protein in both post-vaccine and post-infection Long COVID syndromes. Professor Clancy highlights the similarities between these presentations and their response to a specific treatment approach. The use of a drug called ivermectin, which has shown high affinity for binding to the spike protein, is introduced. Preliminary findings suggest that ivermectin can improve oxygen saturation in patients with low levels, potentially by preventing red blood cell clumping caused by the spike protein. The host and Professor Clancy share their experiences with treating patients using ivermectin, noting the need for further research on long-term safety and efficacy.
📊 Patient Symptoms and Clinical Presentation
The conversation delves into the specific symptoms presented by patients with post-vaccine injury and Long COVID, such as chest pain, fatigue, and cognitive impairments. Professor Clancy describes the process of evaluating these symptoms using a self-assessment scale provided by the patients. A case study is presented, illustrating the severe impact of the illness on a patient's daily life and the potential for significant improvement through treatment.
📈 Graphical Representation of Treatment Response
Professor Clancy presents a graphical representation of a patient's response to ivermectin treatment, showing dramatic improvements across various symptoms. The graph illustrates a complete remission of symptoms during the treatment period, followed by a relapse after discontinuation. The discussion emphasizes the need for further research to understand the long-term effects and optimal dosing regimens of ivermectin.
🧠 Mechanisms of Action and Potential Treatments
The dialogue explores the potential mechanisms by which ivermectin may be effective, including its ability to bind to and block the spike protein, thereby preventing viral entry into cells and reducing inflammation in small blood vessels. The possibility of ivermectin's role in treating peripheral neuropathy and POTS (Postural Orthostatic Tachycardia Syndrome) is also discussed, with a focus on the importance of blocking the spike protein to alleviate symptoms.
💊 Repurposing Drugs and the Role of Clinical Experience
The speakers discuss the use of repurposed drugs like ivermectin and hydroxychloroquine in treating Long COVID, emphasizing the value of clinical experience over large-scale randomized control trials. They express frustration with the pharmaceutical industry's focus on new drugs and the reluctance to recognize the potential of existing, well-understood medications. The conversation also touches on the importance of individualized treatment plans and the role of the patient-physician relationship in managing complex conditions.
🌿 The Role of Microbiome and Immune Resilience
The final paragraph discusses the potential role of the gut microbiome in enhancing immune resilience and the mucosal immune response to viruses. The concept of improving the body's ability to handle viruses like COVID-19 is explored, with a focus on the importance of the interplay between the gut and the respiratory system. The conversation concludes with a call to action for healthcare professionals to explore these hypotheses and to optimize patient care based on the latest scientific understanding.
Mindmap
Keywords
💡Long COVID
💡Postvaccine Syndrome
💡Ivermectin (Icton)
💡Spike Protein
💡Oxygen Saturation
💡Evidence-based Communication
💡Randomized Control Trials (RCTs)
💡POTS Syndrome
💡Peripheral Neuropathy
💡Hydroxychloroquine
💡Immune Resilience
Highlights
Professor Robert Clancy discusses his clinical work on a new medium called evidence-based communication.
Clancy emphasizes not prescribing medications or medical interventions based on the discussion for the general public.
An appeal to doctors and researchers to explore the discussed findings further through randomized control trials.
Clancy has observed similarities between post-vaccine syndrome and post-infection long COVID, both responding to a similar treatment approach.
The use of a drug with high affinity for binding to the spike protein is explored as a potential treatment for long COVID and post-vaccine syndrome.
A recent study showed that treating patients with low oxygen saturation with this drug can normalize it within 24 hours.
The drug prevents red blood cells from clumping together, improving oxygen transfer from the lungs into the blood.
Clancy has treated a small number of patients with promising short-term results, raising many questions for long-term use.
The potential for the treatment to apply to a range of related disorders of chronic fatigue syndrome is discussed.
Clinical features of patients with post-vaccine injury include chest pain, passing out, fatigue, and cognitive impairment.
A patient's self-reported data shows dramatic improvements in symptoms after treatment, followed by a relapse post-treatment cessation.
The treatment's mechanism is likened to competitive inhibition, blocking the spike protein and preventing red blood cell clumping.
The parallels between the effects of the spike protein and conditions like diabetes in terms of neuropathy are highlighted.
The possibility of an intracellular effect of the drug in reducing spike protein production is considered.
Clancy discusses the importance of individualized treatment plans and the role of the patient in their management.
The potential role of hydroxychloroquine and zinc in treating long COVID by increasing zinc intake into cells is mentioned.
Clancy stresses the need for more doctors to step up and start treating patients with post-COVID conditions based on the emerging evidence.
The conversation underscores the importance of evidence-based discussions and the potential for new research avenues, including PhDs and MDs, emerging from such dialogues.
Transcripts
Browse More Related Video
5.0 / 5 (0 votes)
Thanks for rating: